Home > Search Results

Results: 1 to 20 of 22

Spinal Injury: Assessment and Initial Management

The scope of this guideline is the assessment, imaging and early management of spinal injury and does not address rehabilitation. It is important to recognise that early management is intrinsically connected to rehabilitation and some later complications may be avoided with changes in early care. Early and ongoing collaborative multidisciplinary care across a trauma network is vital in ensuring that the patient with a spinal injury receives the best possible care.

NICE Guideline - National Clinical Guideline Centre (UK).

Version: February 2016
Show search results within this document

Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities [Internet]

The purpose of this project was to provide national guidance on the optimal use of 99mTc during a situation of reduced supply. To accomplish this, our objective at CADTH was:

Optimal Use Report - Canadian Agency for Drugs and Technologies in Health.

Version: 2012

Stereotactic Body Radiation Therapy [Internet]

Conduct a systematic literature scan for published data for the treatment of stereotactic body radiation therapy (SBRT) and provide a broad overview of the current state of SBRT for solid malignant tumors.

Comparative Effectiveness Technical Briefs - Agency for Healthcare Research and Quality (US).

Version: May 2011
Show search results within this document

Particle Beam Radiation Therapies for Cancer [Internet]

Radiotherapy with charged particles can potentially deliver maximal doses while minimizing irradiation of surrounding tissues. It may be more effective or less harmful than other forms of radiotherapy for some cancers. Currently, seven centers in the United States have facilities for particle (proton) irradiation, and at least four are under construction, each costing between $100 and $225 million. The aim of this Technical Brief was to survey the evidence on particle beam radiotherapy.

Comparative Effectiveness Technical Briefs - Agency for Healthcare Research and Quality (US).

Version: November 2009
Show search results within this document

Prostate Cancer: Diagnosis and Treatment

The original Prostate Cancer: Diagnosis and Treatment Guideline published in 2008 was the first clinical guideline produced by the National Collaborating Centre for Cancer (NCC-C); accordingly this is now the first NCC-C clinical guideline to be reviewed and updated. Many areas of the original guideline are unchanged as there is little or no new evidence; other aspects have been completely rewritten. As ever there are still many topics where the research evidence is incomplete or conflicting, and so the Guideline Development Group (GDG) have been required to reach a consensus using the evidence available to them in several areas. In places where it was clear that further work needed to be done, new research recommendations have been made which we hope will be used as the basis for future research work.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: January 2014

Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

Expert-reviewed information summary about the health problems that appear after cancer treatment has ended.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 14, 2017

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care [Internet]

This report evaluates the level of evidence currently available to support the effectiveness and safety of using recombinant activated coagulation factor VII (rFVIIa) for clinical indications not approved by the U. S. Food and Drug Administration (FDA). rFVIIa is approved for a variety of uses in hemophilia patients who have developed antibody inhibitors that compromise the use of standard factor replacement. Use of this costly biologic product has expanded beyond these hemophilia-related indications to encompass a range of off-label uses, most of which are in-hospital uses. These uses differ substantially from the drug’s FDA approved label. The purpose of this report is two-fold: (1) To document the full range of clinical indications for which rFVIIa is being used and the types of studies available to evaluate these uses and (2) To provide a comparative effectiveness review of rFVIIa vs. usual care for several in-hospital clinical indications: intracranial hemorrhage, massive bleeding secondary to trauma, and the selected surgical procedures of cardiac surgery, liver transplantation, and prostatectomy.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: May 2010
Show search results within this document

Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression

It is difficult to know what the true incidence of metastatic spinal cord compression (MSCC) is in England and Wales because the cases are not systematically recorded. However, evidence from an audit carried out in Scotland between 1997 and 1999 and from a published study from Ontario, Canada, suggests that the incidence may be up to 80 cases per million population per year. This would mean around 4000 cases per year in England and Wales or more than 100 cases per cancer network per year.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: November 2008
Show search results within this document

EOS 2D/3D X-ray Imaging System: A Systematic Review and Economic Evaluation

EOS is a biplane X-ray imaging system manufactured by EOS Imaging (formerly Biospace Med, Paris, France). It uses slot-scanning technology to produce a high-quality image with less irradiation than standard imaging techniques.

Health Technology Assessment - NIHR Journals Library.

Version: March 2012
Show search results within this document

Bladder Cancer: Diagnosis and Management

Bladder cancer is the seventh most common cancer in the UK, with just over 10,000 cases diagnosed each year (CRUK, 2013a). These are unevenly split between men (fourth most common cancer) and women (11th most common cancer).

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: February 2015

Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®): Health Professional Version

Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: December 16, 2016

Fractures (Non-Complex): Assessment and Management

Two of the five guidelines in the NICE trauma suite relate to fractures. These are titled non-complex and complex fractures. In broad terms, non-complex fractures are those likely to be treated at the receiving hospital, whereas complex fractures require transfer or the consideration of transfer of the injured person to a specialist.

NICE Guideline - National Clinical Guideline Centre (UK).

Version: February 2016

Gastrointestinal Complications (PDQ®): Health Professional Version

Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 10, 2017

Acupuncture (PDQ®): Health Professional Version

Expert-reviewed information summary about acupuncture as a treatment for people with cancer or cancer-related disorders.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 20, 2016

Advanced Breast Cancer: Diagnosis and Treatment

Breast cancer is the most common cancer for women in England and Wales, with about 37,000 new cases diagnosed and 11,000 deaths recorded in England and Wales each year. In men breast cancer is rare, with about 270 cases diagnosed, and 70 deaths in England and Wales each year. Of these new cases in women and men, around 10% are diagnosed in the advanced stages, when the tumour has spread significantly within the breast or to other organs of the body. In addition, there is a significant number of women who have been previously treated with curative intent who subsequently develop either a local recurrence or metastases. Over recent years there have been important developments in the investigation and management of these patients including new chemotherapy, and biological and hormonal agents. There is some evidence of practice variation across the country and of patchy availability of certain treatments and procedures. A clinical guideline will help to address these issues and offer guidance on best practice.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: February 2009

Childhood Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 16, 2017

Cancer Pain (PDQ®): Health Professional Version

Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 17, 2017

Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation [Internet]

In 2009, the U.S. Preventive Services Task Force (USPSTF) recommended biennial screening mammography for women age 50 to 74 years, and based decisions for earlier screening on individual patient context and values. Evidence was insufficient to recommend screening beyond age 75.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: January 2016
Show search results within this document

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation

Study found that there is limited evidence on the clinical effectiveness and cost-effectiveness of ablative and other minimally invasive therapies for treating people with liver metastases. Results are presented for a number of ablative and minimally invasive therapies, but all studies had methodological shortcomings, few had a comparator group and there were with limited analyses and many uncertainties. There is scope for further research.

Health Technology Assessment - NIHR Journals Library.

Version: January 2014
Show search results within this document

Childhood Soft Tissue Sarcoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 16, 2017

Systematic Reviews in PubMed

See all (7)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...